{"Title": "Multiplex genome-edited T-cell manufacturing platform for \"off-the-shelf\" adoptive T-cell immunotherapies", "Year": 2015, "Source": "Cancer Res.", "Volume": "75", "Issue": 18, "Art.No": null, "PageStart": 3853, "PageEnd": 3864, "CitedBy": 234, "DOI": "10.1158/0008-5472.CAN-14-3321", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942903938&origin=inward", "Abstract": "\u00a9 2015 American Association for Cancer Research.Adoptive immunotherapy using autologous T cells endowed with chimeric antigen receptors (CAR) has emerged as a powerful means of treating cancer. However, a limitation of this approach is that autologous CAR T cells must be generated on a custom-made basis. Here we show that electroporation of transcription activator-like effector nuclease (TALEN) mRNA allows highly efficient multiplex gene editing in primary human T cells. We use this TALEN-mediated editing approach to develop a process for the large-scale manufacturing of T cells deficient in expression of both their \u03b1\u03b2 T-cell receptor (TCR) and CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent. Functionally, T cells manufactured with this process do not mediate graft-versus-host reactions and are rendered resistant to destruction by alemtuzumab. These characteristics enable the administration of alemtuzumab concurrently or prior to engineered T cells, supporting their engraftment. Furthermore, endowing the TALEN-engineered cells with aCD19CARled to efficient destruction of CD19+ tumor targets even in the presence of the chemotherapeutic agent. These results demonstrate the applicability of TALEN-mediated genome editing to a scalable process, which enables the manufacturing of third-party CAR T-cell immunotherapies against arbitrary targets. As such, CAR T-cell immunotherapies can therefore be used in an \"off-the-shelf\" manner akin to other biologic immunopharmaceuticals.", "AuthorKeywords": null, "IndexKeywords": ["Animals", "Antibodies, Monoclonal", "Antibodies, Monoclonal, Humanized", "Antigens, CD", "Antigens, CD19", "Antigens, Neoplasm", "Base Sequence", "Cytotoxicity, Immunologic", "Drug Resistance", "Gene Knockout Techniques", "Glycoproteins", "Graft vs Host Disease", "Humans", "Immunotherapy, Adoptive", "Lymphocyte Activation", "Lymphoma", "Mice", "Mice, Mutant Strains", "Molecular Sequence Data", "Receptors, Antigen, T-Cell", "Receptors, Antigen, T-Cell, alpha-beta", "Recombinant Fusion Proteins", "RNA, Messenger", "T-Lymphocytes", "Transfection", "Xenograft Model Antitumor Assays"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84942903938", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"56884234100": {"Name": "Philip L.P.B.", "AuthorID": "56884234100", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "35210724100": {"Name": "Le Clerre D.", "AuthorID": "35210724100", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "36730699000": {"Name": "Chion-Sotinel I.", "AuthorID": "36730699000", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "8790176300": {"Name": "Derniame S.", "AuthorID": "8790176300", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "55481399300": {"Name": "Potrel P.", "AuthorID": "55481399300", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "56884249600": {"Name": "Bas C.", "AuthorID": "56884249600", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "35198510700": {"Name": "Lemaire L.", "AuthorID": "35198510700", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "6603328822": {"Name": "Galetto R.", "AuthorID": "6603328822", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "57205563265": {"Name": "Lebuhotel C.", "AuthorID": "57205563265", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "55670625700": {"Name": "Eyquem J.", "AuthorID": "55670625700", "AffiliationID": "60009343", "AffiliationName": "Memorial Sloan Kettering Cancer Center"}, "6602700811": {"Name": "Duclert A.", "AuthorID": "6602700811", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "6508228723": {"Name": "Gouble A.", "AuthorID": "6508228723", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "57201181771": {"Name": "Arnould S.", "AuthorID": "57201181771", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "57209776898": {"Name": "Smith J.", "AuthorID": "57209776898", "AffiliationID": "60119192", "AffiliationName": "Cellectis"}, "56884771600": {"Name": "Schiffer-Mannioui C.", "AuthorID": "56884771600", "AffiliationID": "60109234, 60022148", "AffiliationName": "Department of Haematology, UCL Cancer Institute, University College London"}, "56884070200": {"Name": "Cheung G.W.K.", "AuthorID": "56884070200", "AffiliationID": "60109234, 60022148", "AffiliationName": "Department of Haematology, UCL Cancer Institute, University College London"}, "35416735200": {"Name": "Peggs K.", "AuthorID": "35416735200", "AffiliationID": "60109234, 60022148", "AffiliationName": "Department of Haematology, UCL Cancer Institute, University College London"}, "57211009223": {"Name": "Pule M.", "AuthorID": "57211009223", "AffiliationID": "60109234, 60022148", "AffiliationName": "Department of Haematology, UCL Cancer Institute, University College London"}, "7004823266": {"Name": "Scharenberg A.M.", "AuthorID": "7004823266", "AffiliationID": "60015481, 60018922", "AffiliationName": "Department of Pediatrics, University of Washington, Seattle Children's Research Institute"}}}